\n<\/p>\n
\n \n \n Add topic to email alerts \n <\/span> \n <\/p>\n\n\n \n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nThe 5th <\/sup>U.S. Circuit Court of Appeals is temporarily halting mail-order mifepristone access.<\/li>\nThe ruling is expected to be appealed to the Supreme Court.<\/li>\n<\/ul>\nThe 5th Circuit Court of Appeals has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access, court documents show.<\/p>\nThe ruling halts mail-order telehealth access even in states without restrictions on abortions, according to reporting by The <\/i>Associated Press. <\/i>It will likely be appealed to the Supreme Court.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n A federal appeals court has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access. \n <\/figcaption> \n <\/figure>\nThe case was filed against the FDA by the state of Louisiana and \u201ca woman who said she was coerced into taking abortion pills,\u201d The A<\/i>P<\/i> reported. The judges sided with the plaintiffs that mail-order mifepristone \u201ccancels Louisiana\u2019s ban on medical abortions and undermines its policy that \u2018every unborn child is human being from the moment of conception and is, therefore, a legal person.\u2019\u201d<\/p>\nIn a statement emailed to Healio, ACOG Chief Legal Officer Molly Meegan, JD,<\/b> said the ruling \u201ccreates more confusion for patients and physicians and puts pregnant patients seeking reproductive health care, including those who need mifepristone for miscarriage management, immediately at risk.\u201d<\/p>\n\u201cMifepristone is one of the most studied medications on the market and is conclusively safe, including when prescribed through telehealth and dispensed via mail,\u201d Meegan said. \u201cThe court\u2019s decision to restrict access to this medication infringes on patients\u2019 access to health care, especially for people who rely on telehealth or face barriers to care. More than 2 decades of evidence and volumes of research prove mifepristone is a safe, essential part of reproductive health care.\u201d<\/p>\nEach year, more than 60% of abortions in the United States involve medication abortion, which is typically a combination of mifepristone and misoprostol, according to a press release from the Center for Reproductive Rights. About one-quarter of all U.S. abortions are now provided through telehealth, \u201ca two-fold increase since Roe v. Wade<\/i> was overturned,\u201d the release said.<\/p>\n\u201cTelehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned,\u201d Nancy Northup,<\/b> president and CEO of the Center for Reproductive Rights, said in the release. \u201cThis [ruling] isn\u2019t about science \u2014 it\u2019s about making abortion as difficult, expensive and unreachable as possible.\u201d<\/p>\nThe Louisiana ruling is one of several ongoing cases, the Center for Reproductive Rights said. Other cases in Texas and Missouri \u201ccould go even further, including by directing the FDA to withdraw its approval of mifepristone altogether,\u201d according to the organization.<\/p>\n The FDA initiated a comprehensive review of mifepristone in September 2025 after 22 Republican state attorneys general sent a letter to HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary, MD, MPH, outlining their concerns with the drug. In the letter, the state attorneys general claimed the drug is not as safe and effective as stated on the drug\u2019s label. The FDA\u2019s review is ongoing. <\/p>\n\u201cHundreds of studies confirm mifepristone\u2019s safety, and 7.5 million Americans have used the drug since it was approved by the FDA in 2000,\u201d according to the Center for Reproductive Rights.<\/p>\nIn February, a coalition of 15 organizations led by ACOG filed an amicus brief supporting the FDA\u2019s 2023 decision to end in-person requirements for mifepristone dispensing. <\/p>\n\u201cWe at ACOG will redouble our efforts to ensure that patients\u2019 needs, science and evidence \u2014 not ideology \u2014 guide medical decisions relating to reproductive health care,\u201d Meegan said. \u201cSafe, essential reproductive health care, including mifepristone, should be available to the women of America without unnecessary burdens and barriers; they deserve no less.\u201d <\/p>\n
\n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nThe 5th <\/sup>U.S. Circuit Court of Appeals is temporarily halting mail-order mifepristone access.<\/li>\nThe ruling is expected to be appealed to the Supreme Court.<\/li>\n<\/ul>\nThe 5th Circuit Court of Appeals has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access, court documents show.<\/p>\nThe ruling halts mail-order telehealth access even in states without restrictions on abortions, according to reporting by The <\/i>Associated Press. <\/i>It will likely be appealed to the Supreme Court.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n A federal appeals court has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access. \n <\/figcaption> \n <\/figure>\nThe case was filed against the FDA by the state of Louisiana and \u201ca woman who said she was coerced into taking abortion pills,\u201d The A<\/i>P<\/i> reported. The judges sided with the plaintiffs that mail-order mifepristone \u201ccancels Louisiana\u2019s ban on medical abortions and undermines its policy that \u2018every unborn child is human being from the moment of conception and is, therefore, a legal person.\u2019\u201d<\/p>\nIn a statement emailed to Healio, ACOG Chief Legal Officer Molly Meegan, JD,<\/b> said the ruling \u201ccreates more confusion for patients and physicians and puts pregnant patients seeking reproductive health care, including those who need mifepristone for miscarriage management, immediately at risk.\u201d<\/p>\n\u201cMifepristone is one of the most studied medications on the market and is conclusively safe, including when prescribed through telehealth and dispensed via mail,\u201d Meegan said. \u201cThe court\u2019s decision to restrict access to this medication infringes on patients\u2019 access to health care, especially for people who rely on telehealth or face barriers to care. More than 2 decades of evidence and volumes of research prove mifepristone is a safe, essential part of reproductive health care.\u201d<\/p>\nEach year, more than 60% of abortions in the United States involve medication abortion, which is typically a combination of mifepristone and misoprostol, according to a press release from the Center for Reproductive Rights. About one-quarter of all U.S. abortions are now provided through telehealth, \u201ca two-fold increase since Roe v. Wade<\/i> was overturned,\u201d the release said.<\/p>\n\u201cTelehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned,\u201d Nancy Northup,<\/b> president and CEO of the Center for Reproductive Rights, said in the release. \u201cThis [ruling] isn\u2019t about science \u2014 it\u2019s about making abortion as difficult, expensive and unreachable as possible.\u201d<\/p>\nThe Louisiana ruling is one of several ongoing cases, the Center for Reproductive Rights said. Other cases in Texas and Missouri \u201ccould go even further, including by directing the FDA to withdraw its approval of mifepristone altogether,\u201d according to the organization.<\/p>\n The FDA initiated a comprehensive review of mifepristone in September 2025 after 22 Republican state attorneys general sent a letter to HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary, MD, MPH, outlining their concerns with the drug. In the letter, the state attorneys general claimed the drug is not as safe and effective as stated on the drug\u2019s label. The FDA\u2019s review is ongoing. <\/p>\n\u201cHundreds of studies confirm mifepristone\u2019s safety, and 7.5 million Americans have used the drug since it was approved by the FDA in 2000,\u201d according to the Center for Reproductive Rights.<\/p>\nIn February, a coalition of 15 organizations led by ACOG filed an amicus brief supporting the FDA\u2019s 2023 decision to end in-person requirements for mifepristone dispensing. <\/p>\n\u201cWe at ACOG will redouble our efforts to ensure that patients\u2019 needs, science and evidence \u2014 not ideology \u2014 guide medical decisions relating to reproductive health care,\u201d Meegan said. \u201cSafe, essential reproductive health care, including mifepristone, should be available to the women of America without unnecessary burdens and barriers; they deserve no less.\u201d <\/p>\n
“ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nThe 5th <\/sup>U.S. Circuit Court of Appeals is temporarily halting mail-order mifepristone access.<\/li>\nThe ruling is expected to be appealed to the Supreme Court.<\/li>\n<\/ul>\nThe 5th Circuit Court of Appeals has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access, court documents show.<\/p>\nThe ruling halts mail-order telehealth access even in states without restrictions on abortions, according to reporting by The <\/i>Associated Press. <\/i>It will likely be appealed to the Supreme Court.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n A federal appeals court has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access. \n <\/figcaption> \n <\/figure>\nThe case was filed against the FDA by the state of Louisiana and \u201ca woman who said she was coerced into taking abortion pills,\u201d The A<\/i>P<\/i> reported. The judges sided with the plaintiffs that mail-order mifepristone \u201ccancels Louisiana\u2019s ban on medical abortions and undermines its policy that \u2018every unborn child is human being from the moment of conception and is, therefore, a legal person.\u2019\u201d<\/p>\nIn a statement emailed to Healio, ACOG Chief Legal Officer Molly Meegan, JD,<\/b> said the ruling \u201ccreates more confusion for patients and physicians and puts pregnant patients seeking reproductive health care, including those who need mifepristone for miscarriage management, immediately at risk.\u201d<\/p>\n\u201cMifepristone is one of the most studied medications on the market and is conclusively safe, including when prescribed through telehealth and dispensed via mail,\u201d Meegan said. \u201cThe court\u2019s decision to restrict access to this medication infringes on patients\u2019 access to health care, especially for people who rely on telehealth or face barriers to care. More than 2 decades of evidence and volumes of research prove mifepristone is a safe, essential part of reproductive health care.\u201d<\/p>\nEach year, more than 60% of abortions in the United States involve medication abortion, which is typically a combination of mifepristone and misoprostol, according to a press release from the Center for Reproductive Rights. About one-quarter of all U.S. abortions are now provided through telehealth, \u201ca two-fold increase since Roe v. Wade<\/i> was overturned,\u201d the release said.<\/p>\n\u201cTelehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned,\u201d Nancy Northup,<\/b> president and CEO of the Center for Reproductive Rights, said in the release. \u201cThis [ruling] isn\u2019t about science \u2014 it\u2019s about making abortion as difficult, expensive and unreachable as possible.\u201d<\/p>\nThe Louisiana ruling is one of several ongoing cases, the Center for Reproductive Rights said. Other cases in Texas and Missouri \u201ccould go even further, including by directing the FDA to withdraw its approval of mifepristone altogether,\u201d according to the organization.<\/p>\n The FDA initiated a comprehensive review of mifepristone in September 2025 after 22 Republican state attorneys general sent a letter to HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary, MD, MPH, outlining their concerns with the drug. In the letter, the state attorneys general claimed the drug is not as safe and effective as stated on the drug\u2019s label. The FDA\u2019s review is ongoing. <\/p>\n\u201cHundreds of studies confirm mifepristone\u2019s safety, and 7.5 million Americans have used the drug since it was approved by the FDA in 2000,\u201d according to the Center for Reproductive Rights.<\/p>\nIn February, a coalition of 15 organizations led by ACOG filed an amicus brief supporting the FDA\u2019s 2023 decision to end in-person requirements for mifepristone dispensing. <\/p>\n\u201cWe at ACOG will redouble our efforts to ensure that patients\u2019 needs, science and evidence \u2014 not ideology \u2014 guide medical decisions relating to reproductive health care,\u201d Meegan said. \u201cSafe, essential reproductive health care, including mifepristone, should be available to the women of America without unnecessary burdens and barriers; they deserve no less.\u201d <\/p>\n
Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nThe 5th <\/sup>U.S. Circuit Court of Appeals is temporarily halting mail-order mifepristone access.<\/li>\nThe ruling is expected to be appealed to the Supreme Court.<\/li>\n<\/ul>\nThe 5th Circuit Court of Appeals has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access, court documents show.<\/p>\nThe ruling halts mail-order telehealth access even in states without restrictions on abortions, according to reporting by The <\/i>Associated Press. <\/i>It will likely be appealed to the Supreme Court.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n A federal appeals court has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access. \n <\/figcaption> \n <\/figure>\nThe case was filed against the FDA by the state of Louisiana and \u201ca woman who said she was coerced into taking abortion pills,\u201d The A<\/i>P<\/i> reported. The judges sided with the plaintiffs that mail-order mifepristone \u201ccancels Louisiana\u2019s ban on medical abortions and undermines its policy that \u2018every unborn child is human being from the moment of conception and is, therefore, a legal person.\u2019\u201d<\/p>\nIn a statement emailed to Healio, ACOG Chief Legal Officer Molly Meegan, JD,<\/b> said the ruling \u201ccreates more confusion for patients and physicians and puts pregnant patients seeking reproductive health care, including those who need mifepristone for miscarriage management, immediately at risk.\u201d<\/p>\n\u201cMifepristone is one of the most studied medications on the market and is conclusively safe, including when prescribed through telehealth and dispensed via mail,\u201d Meegan said. \u201cThe court\u2019s decision to restrict access to this medication infringes on patients\u2019 access to health care, especially for people who rely on telehealth or face barriers to care. More than 2 decades of evidence and volumes of research prove mifepristone is a safe, essential part of reproductive health care.\u201d<\/p>\nEach year, more than 60% of abortions in the United States involve medication abortion, which is typically a combination of mifepristone and misoprostol, according to a press release from the Center for Reproductive Rights. About one-quarter of all U.S. abortions are now provided through telehealth, \u201ca two-fold increase since Roe v. Wade<\/i> was overturned,\u201d the release said.<\/p>\n\u201cTelehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned,\u201d Nancy Northup,<\/b> president and CEO of the Center for Reproductive Rights, said in the release. \u201cThis [ruling] isn\u2019t about science \u2014 it\u2019s about making abortion as difficult, expensive and unreachable as possible.\u201d<\/p>\nThe Louisiana ruling is one of several ongoing cases, the Center for Reproductive Rights said. Other cases in Texas and Missouri \u201ccould go even further, including by directing the FDA to withdraw its approval of mifepristone altogether,\u201d according to the organization.<\/p>\n The FDA initiated a comprehensive review of mifepristone in September 2025 after 22 Republican state attorneys general sent a letter to HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary, MD, MPH, outlining their concerns with the drug. In the letter, the state attorneys general claimed the drug is not as safe and effective as stated on the drug\u2019s label. The FDA\u2019s review is ongoing. <\/p>\n\u201cHundreds of studies confirm mifepristone\u2019s safety, and 7.5 million Americans have used the drug since it was approved by the FDA in 2000,\u201d according to the Center for Reproductive Rights.<\/p>\nIn February, a coalition of 15 organizations led by ACOG filed an amicus brief supporting the FDA\u2019s 2023 decision to end in-person requirements for mifepristone dispensing. <\/p>\n\u201cWe at ACOG will redouble our efforts to ensure that patients\u2019 needs, science and evidence \u2014 not ideology \u2014 guide medical decisions relating to reproductive health care,\u201d Meegan said. \u201cSafe, essential reproductive health care, including mifepristone, should be available to the women of America without unnecessary burdens and barriers; they deserve no less.\u201d <\/p>\n
The 5th Circuit Court of Appeals has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access, court documents show.<\/p>\n
The ruling halts mail-order telehealth access even in states without restrictions on abortions, according to reporting by The <\/i>Associated Press. <\/i>It will likely be appealed to the Supreme Court.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n A federal appeals court has temporarily restored a rule the FDA lifted in 2023 that requires mifepristone to be dispensed in person, blocking mail-order access. \n <\/figcaption> \n <\/figure>\nThe case was filed against the FDA by the state of Louisiana and \u201ca woman who said she was coerced into taking abortion pills,\u201d The A<\/i>P<\/i> reported. The judges sided with the plaintiffs that mail-order mifepristone \u201ccancels Louisiana\u2019s ban on medical abortions and undermines its policy that \u2018every unborn child is human being from the moment of conception and is, therefore, a legal person.\u2019\u201d<\/p>\nIn a statement emailed to Healio, ACOG Chief Legal Officer Molly Meegan, JD,<\/b> said the ruling \u201ccreates more confusion for patients and physicians and puts pregnant patients seeking reproductive health care, including those who need mifepristone for miscarriage management, immediately at risk.\u201d<\/p>\n\u201cMifepristone is one of the most studied medications on the market and is conclusively safe, including when prescribed through telehealth and dispensed via mail,\u201d Meegan said. \u201cThe court\u2019s decision to restrict access to this medication infringes on patients\u2019 access to health care, especially for people who rely on telehealth or face barriers to care. More than 2 decades of evidence and volumes of research prove mifepristone is a safe, essential part of reproductive health care.\u201d<\/p>\nEach year, more than 60% of abortions in the United States involve medication abortion, which is typically a combination of mifepristone and misoprostol, according to a press release from the Center for Reproductive Rights. About one-quarter of all U.S. abortions are now provided through telehealth, \u201ca two-fold increase since Roe v. Wade<\/i> was overturned,\u201d the release said.<\/p>\n\u201cTelehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned,\u201d Nancy Northup,<\/b> president and CEO of the Center for Reproductive Rights, said in the release. \u201cThis [ruling] isn\u2019t about science \u2014 it\u2019s about making abortion as difficult, expensive and unreachable as possible.\u201d<\/p>\nThe Louisiana ruling is one of several ongoing cases, the Center for Reproductive Rights said. Other cases in Texas and Missouri \u201ccould go even further, including by directing the FDA to withdraw its approval of mifepristone altogether,\u201d according to the organization.<\/p>\n The FDA initiated a comprehensive review of mifepristone in September 2025 after 22 Republican state attorneys general sent a letter to HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary, MD, MPH, outlining their concerns with the drug. In the letter, the state attorneys general claimed the drug is not as safe and effective as stated on the drug\u2019s label. The FDA\u2019s review is ongoing. <\/p>\n\u201cHundreds of studies confirm mifepristone\u2019s safety, and 7.5 million Americans have used the drug since it was approved by the FDA in 2000,\u201d according to the Center for Reproductive Rights.<\/p>\nIn February, a coalition of 15 organizations led by ACOG filed an amicus brief supporting the FDA\u2019s 2023 decision to end in-person requirements for mifepristone dispensing. <\/p>\n\u201cWe at ACOG will redouble our efforts to ensure that patients\u2019 needs, science and evidence \u2014 not ideology \u2014 guide medical decisions relating to reproductive health care,\u201d Meegan said. \u201cSafe, essential reproductive health care, including mifepristone, should be available to the women of America without unnecessary burdens and barriers; they deserve no less.\u201d <\/p>\n
The case was filed against the FDA by the state of Louisiana and \u201ca woman who said she was coerced into taking abortion pills,\u201d The A<\/i>P<\/i> reported. The judges sided with the plaintiffs that mail-order mifepristone \u201ccancels Louisiana\u2019s ban on medical abortions and undermines its policy that \u2018every unborn child is human being from the moment of conception and is, therefore, a legal person.\u2019\u201d<\/p>\n
In a statement emailed to Healio, ACOG Chief Legal Officer Molly Meegan, JD,<\/b> said the ruling \u201ccreates more confusion for patients and physicians and puts pregnant patients seeking reproductive health care, including those who need mifepristone for miscarriage management, immediately at risk.\u201d<\/p>\n
\u201cMifepristone is one of the most studied medications on the market and is conclusively safe, including when prescribed through telehealth and dispensed via mail,\u201d Meegan said. \u201cThe court\u2019s decision to restrict access to this medication infringes on patients\u2019 access to health care, especially for people who rely on telehealth or face barriers to care. More than 2 decades of evidence and volumes of research prove mifepristone is a safe, essential part of reproductive health care.\u201d<\/p>\n
Each year, more than 60% of abortions in the United States involve medication abortion, which is typically a combination of mifepristone and misoprostol, according to a press release from the Center for Reproductive Rights. About one-quarter of all U.S. abortions are now provided through telehealth, \u201ca two-fold increase since Roe v. Wade<\/i> was overturned,\u201d the release said.<\/p>\n
\u201cTelehealth has been the last bridge to care for many seeking abortion, which is precisely why Louisiana officials want it banned,\u201d Nancy Northup,<\/b> president and CEO of the Center for Reproductive Rights, said in the release. \u201cThis [ruling] isn\u2019t about science \u2014 it\u2019s about making abortion as difficult, expensive and unreachable as possible.\u201d<\/p>\n
The Louisiana ruling is one of several ongoing cases, the Center for Reproductive Rights said. Other cases in Texas and Missouri \u201ccould go even further, including by directing the FDA to withdraw its approval of mifepristone altogether,\u201d according to the organization.<\/p>\n
The FDA initiated a comprehensive review of mifepristone in September 2025 after 22 Republican state attorneys general sent a letter to HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Martin A. Makary, MD, MPH, outlining their concerns with the drug. In the letter, the state attorneys general claimed the drug is not as safe and effective as stated on the drug\u2019s label. The FDA\u2019s review is ongoing. <\/p>\n
\u201cHundreds of studies confirm mifepristone\u2019s safety, and 7.5 million Americans have used the drug since it was approved by the FDA in 2000,\u201d according to the Center for Reproductive Rights.<\/p>\n
In February, a coalition of 15 organizations led by ACOG filed an amicus brief supporting the FDA\u2019s 2023 decision to end in-person requirements for mifepristone dispensing. <\/p>\n
\u201cWe at ACOG will redouble our efforts to ensure that patients\u2019 needs, science and evidence \u2014 not ideology \u2014 guide medical decisions relating to reproductive health care,\u201d Meegan said. \u201cSafe, essential reproductive health care, including mifepristone, should be available to the women of America without unnecessary burdens and barriers; they deserve no less.\u201d <\/p>\n